Cargando…

Patients with high serum substance P levels previously to liver transplantation for hepatocellular carcinoma have higher risk of one-year liver transplantation mortality

PURPOSE: Substance P is a tachykinins family member with inflammatory effects. Higher circulating levels of substance P have been found in patients with liver diseases and in patients with higher severity of liver diseases. The objective of this study was to determine whether serum levels of substan...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorente, Leonardo, Rodriguez, Sergio T., Sanz, Pablo, Pérez-Cejas, Antonia, Padilla, Javier, Díaz, Dácil, González, Antonio, Martín, María M., Jiménez, Alejandro, Cerro, Purificación, Barrera, Manuel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940410/
https://www.ncbi.nlm.nih.gov/pubmed/29765559
http://dx.doi.org/10.18632/oncotarget.25097
_version_ 1783321106856280064
author Lorente, Leonardo
Rodriguez, Sergio T.
Sanz, Pablo
Pérez-Cejas, Antonia
Padilla, Javier
Díaz, Dácil
González, Antonio
Martín, María M.
Jiménez, Alejandro
Cerro, Purificación
Barrera, Manuel A.
author_facet Lorente, Leonardo
Rodriguez, Sergio T.
Sanz, Pablo
Pérez-Cejas, Antonia
Padilla, Javier
Díaz, Dácil
González, Antonio
Martín, María M.
Jiménez, Alejandro
Cerro, Purificación
Barrera, Manuel A.
author_sort Lorente, Leonardo
collection PubMed
description PURPOSE: Substance P is a tachykinins family member with inflammatory effects. Higher circulating levels of substance P have been found in patients with liver diseases and in patients with higher severity of liver diseases. The objective of this study was to determine whether serum levels of substance P levels, prior to liver transplantation (LT) for hepatocellular carcinoma (HCC) are associated with one-year LT mortality. MATERIAL AND METHODS: In this observational retrospective unicenter study were included patients with LT for HCC. Serum levels of substance P were measured before LT. The end-point of the study was one-year mortality after LT. RESULTS: We found that one-year survivor patients (n = 127) showed a lower age in liver donors (p = 0.03) and lower levels of serum substance P levels (p = 0.003) than non-survivor patients (n = 15). Logistic regression analysis showed that serum levels of substance P (levels) were associated with one-year mortality (Odds Ratio = 1.011; 95% CI = 1.004–1.018; p = 0.002) controlling for the age of the LT donor. CONCLUSIONS: We believe that our study is the first study reporting data on circulating levels of substance P previously to LT for HCC, and an association between elevated levels of serum substance P before LT and mortality during the first year of LT.
format Online
Article
Text
id pubmed-5940410
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-59404102018-05-15 Patients with high serum substance P levels previously to liver transplantation for hepatocellular carcinoma have higher risk of one-year liver transplantation mortality Lorente, Leonardo Rodriguez, Sergio T. Sanz, Pablo Pérez-Cejas, Antonia Padilla, Javier Díaz, Dácil González, Antonio Martín, María M. Jiménez, Alejandro Cerro, Purificación Barrera, Manuel A. Oncotarget Clinical Research Paper PURPOSE: Substance P is a tachykinins family member with inflammatory effects. Higher circulating levels of substance P have been found in patients with liver diseases and in patients with higher severity of liver diseases. The objective of this study was to determine whether serum levels of substance P levels, prior to liver transplantation (LT) for hepatocellular carcinoma (HCC) are associated with one-year LT mortality. MATERIAL AND METHODS: In this observational retrospective unicenter study were included patients with LT for HCC. Serum levels of substance P were measured before LT. The end-point of the study was one-year mortality after LT. RESULTS: We found that one-year survivor patients (n = 127) showed a lower age in liver donors (p = 0.03) and lower levels of serum substance P levels (p = 0.003) than non-survivor patients (n = 15). Logistic regression analysis showed that serum levels of substance P (levels) were associated with one-year mortality (Odds Ratio = 1.011; 95% CI = 1.004–1.018; p = 0.002) controlling for the age of the LT donor. CONCLUSIONS: We believe that our study is the first study reporting data on circulating levels of substance P previously to LT for HCC, and an association between elevated levels of serum substance P before LT and mortality during the first year of LT. Impact Journals LLC 2018-04-20 /pmc/articles/PMC5940410/ /pubmed/29765559 http://dx.doi.org/10.18632/oncotarget.25097 Text en Copyright: © 2018 Lorente et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Clinical Research Paper
Lorente, Leonardo
Rodriguez, Sergio T.
Sanz, Pablo
Pérez-Cejas, Antonia
Padilla, Javier
Díaz, Dácil
González, Antonio
Martín, María M.
Jiménez, Alejandro
Cerro, Purificación
Barrera, Manuel A.
Patients with high serum substance P levels previously to liver transplantation for hepatocellular carcinoma have higher risk of one-year liver transplantation mortality
title Patients with high serum substance P levels previously to liver transplantation for hepatocellular carcinoma have higher risk of one-year liver transplantation mortality
title_full Patients with high serum substance P levels previously to liver transplantation for hepatocellular carcinoma have higher risk of one-year liver transplantation mortality
title_fullStr Patients with high serum substance P levels previously to liver transplantation for hepatocellular carcinoma have higher risk of one-year liver transplantation mortality
title_full_unstemmed Patients with high serum substance P levels previously to liver transplantation for hepatocellular carcinoma have higher risk of one-year liver transplantation mortality
title_short Patients with high serum substance P levels previously to liver transplantation for hepatocellular carcinoma have higher risk of one-year liver transplantation mortality
title_sort patients with high serum substance p levels previously to liver transplantation for hepatocellular carcinoma have higher risk of one-year liver transplantation mortality
topic Clinical Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940410/
https://www.ncbi.nlm.nih.gov/pubmed/29765559
http://dx.doi.org/10.18632/oncotarget.25097
work_keys_str_mv AT lorenteleonardo patientswithhighserumsubstanceplevelspreviouslytolivertransplantationforhepatocellularcarcinomahavehigherriskofoneyearlivertransplantationmortality
AT rodriguezsergiot patientswithhighserumsubstanceplevelspreviouslytolivertransplantationforhepatocellularcarcinomahavehigherriskofoneyearlivertransplantationmortality
AT sanzpablo patientswithhighserumsubstanceplevelspreviouslytolivertransplantationforhepatocellularcarcinomahavehigherriskofoneyearlivertransplantationmortality
AT perezcejasantonia patientswithhighserumsubstanceplevelspreviouslytolivertransplantationforhepatocellularcarcinomahavehigherriskofoneyearlivertransplantationmortality
AT padillajavier patientswithhighserumsubstanceplevelspreviouslytolivertransplantationforhepatocellularcarcinomahavehigherriskofoneyearlivertransplantationmortality
AT diazdacil patientswithhighserumsubstanceplevelspreviouslytolivertransplantationforhepatocellularcarcinomahavehigherriskofoneyearlivertransplantationmortality
AT gonzalezantonio patientswithhighserumsubstanceplevelspreviouslytolivertransplantationforhepatocellularcarcinomahavehigherriskofoneyearlivertransplantationmortality
AT martinmariam patientswithhighserumsubstanceplevelspreviouslytolivertransplantationforhepatocellularcarcinomahavehigherriskofoneyearlivertransplantationmortality
AT jimenezalejandro patientswithhighserumsubstanceplevelspreviouslytolivertransplantationforhepatocellularcarcinomahavehigherriskofoneyearlivertransplantationmortality
AT cerropurificacion patientswithhighserumsubstanceplevelspreviouslytolivertransplantationforhepatocellularcarcinomahavehigherriskofoneyearlivertransplantationmortality
AT barreramanuela patientswithhighserumsubstanceplevelspreviouslytolivertransplantationforhepatocellularcarcinomahavehigherriskofoneyearlivertransplantationmortality